Navigation Links
Leader of Human Genome Project honored with the Inamori Ethics Prize
Date:9/8/2008

CLEVELAND Francis S. Collins, M.D., Ph.D., a physician-geneticist and leader of the Human Genome Project, has been awarded with the new Inamori Ethics Prize from the Inamori International Center for Ethics and Excellence at Case Western Reserve University.

Modeled after the Nobel and Kyoto Prizes for science, technology, philosophy and the arts, the Inamori Ethics Prize instead honors outstanding international ethical leaders. It is presented annually to an individual who has demonstrated exemplary ethical leadership and whose actions and influence have greatly improved the condition of humankind. The prize recipient also receives a $25,000 cash award intended to support his or her ongoing work.

Noted for his landmark discoveries of disease genes, Collins serves as director of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH). His laboratory is dedicated to researching both rare and common diseases and has discovered a number of important genes, including those responsible for cystic fibrosis, neurofibromatosis, Huntington's disease, adult onset diabetes and Hutchinson-Gilford progeria syndrome, a dramatic form of premature aging.

Collins led the multi-disciplinary, multi-institutional Human Genome Project, an international effort to map and sequence the three billion letters in the human DNA, offering the first complete view of the "human instruction book." With its ultimate goal of improving human health, many consider the project to be one of the most significant scientific undertakings of our time. All the groundbreaking data are now available to the scientific community without restrictions on access or use.

"Throughout his long and distinguished career, Dr. Collins has consistently emphasized the importance of ethical and legal issues in genetics, while at the same time working tirelessly to improving the lives of people worldwide," said Shannon French, director of the In
'/>"/>

Contact: Jason A. Tirotta
jason.tirotta@case.edu
216-368-6890
Case Western Reserve University
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Silicon Valley Technology Leaders LaserCard Corporation and Tesla Motors Sign LaserPass Secure Access Deal
2. Leaderless movement proves illusive
3. Scientists, policymakers and industry leaders gather to discuss ocean iron fertilization
4. Entrust Continues Leadership by Adding Support for Next-generation E-Passports
5. IEEE-USA innovation forum will help prepare US tech leaders to prosper in a global marketplace
6. Stronger EPA leadership needed to improve water quality in Mississippi River
7. Toxic releases down from North American industry leaders, increasing from other facilities
8. Abel to receive posthumous Ocean and Coastal Leadership award
9. UCSD bioengineering grad student wins leadership award
10. Too few women scientists achieving academic leadership positions
11. PNNLs Richard Smith named to prestigious Scientific American 50 list of outstanding leaders

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...O, Calif., Nov. 9 Genencor, a divi... Energy Award" from the American Institute of Chem...amily of enzymes for cellulosic ethanol. Yesterday...e, presented the award to Landon Steele, who is Ma...#174; Product Manager, and Aaron Kelley, who is Se...
(Date:11/9/2009)... culprit responsible for the rapid, mysterious dea...s been found by collaborating scientists at Rutger...itution (WHOI). This same chemical may hold unexp...covered a previously unknown lipid, or fatty compo...g Emiliania huxleyi , a phytoplankton that plays ...
(Date:11/9/2009)..., NOVEMBER 9, 2009 A nutritionist whose research...to the federal Women, Infants and Children (WIC) f...Higgins Award for outstanding achievement in the f...son, Ph.D., MNS, , a professor in the Department o...alifornia, Los Angeles School of Public Health, wi...
Breaking Biology News(10 mins):Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 1SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 2DuraHeart 26amp 3B 238482 3B Third Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio th 59434 1DuraHeart 26amp 3B 238482 3B Third Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio th 59434 2DuraHeart 26amp 3B 238482 3B Third Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio th 59434 3Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 1Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 2Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 3
...he primary targets of HIV-1 infection in the human... study published in the February 2007 issue of the...ndings are likely to guide development of new stra...he majority of HIV-1 infected individuals worldwid...xual contact," explain study authors Dr. Florian H...
...n his Jan. 23 State of the Union address, Presiden...on,s dependency on foreign oil by requiring the pr... and alternative fuels by 2017, roughly five times... gallons by 2012. , Among the most promising alter.... Currently, the main biofuel used in the United S...
...n his Jan. 23 State of the Union address, Presiden...on,s dependency on foreign oil by requiring the pr... and alternative fuels by 2017, roughly five times... gallons by 2012. , Among the most promising alter.... Currently, the main biofuel used in the United S...
Other Biology News:Researchers discover new details about HIV-1 entry and infection 2Custom-made cancer cell attacks 2Custom-made cancer cell attacks 3Cellulosic ethanol: Fuel of the future? 2Cellulosic ethanol: Fuel of the future? 3
(Date:11/5/2009)...O, Nov. 5 Imagenetix, In...t William Spencer, President and CEO of Imagenetix...d annual LD MICRO Conference on Thursday, December...geles. ,, About LD MICRO ,, LD MICRO is a by...inding undervalued companies in the micro-cap spac...
(Date:11/5/2009)...ce Call on Thursday, November 5, 2009 at 4:30 p.m..... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuti... OGXI ) today reported unaudited financial result...ember 30, 2009 and reviewed the Company,s highligh...ing consolidated results reflect the operations of...
(Date:11/5/2009)..., N.Y., Nov. 5 BioSpecif...maceutical company developing first-in-class colla...al results for the third quarter ended September 3...September of this year, the FDA,s Arthritis Adviso... 12-0, the approval of XIAFLEX(TM) for the treatme...
(Date:11/5/2009)...TH, Texas, Nov. 5 Wound ...oday that it has entered into a Letter of Intent t...l Health Technologies, Inc. (OTC Bulletin Board: V...,000 in cash and debt, 4,000,000 shares of WNDM an...DM on the Veriscrip technology being acquired from...
Breaking Biology Technology:Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
...d., March 16 Micromet, Inc. (Nasdaq: MITI ), a ...etary antibodies for the treatment of cancer, infl...the publication of six abstracts for poster presen... place from April 20-24, 2009, in Denver, Colorado... , , , Lutterbuese, R. et al. (2009). H...
...ch 16 PAREXEL experts will address the benefits o... 110th Annual Meeting of the American Society for ... be held at the Gaylord National Resort in Nationa...ocus of PAREXEL,s presence at the ASCPT meeting wi...nd best practice approaches for identifying and se...
...ng expenses decreased by 33% in 2008; Forecast cut...n 2009 , , CTI expects to complete pixantrone ND...ell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC...ial results for the fourth quarter and year ended ... Met primary endpoint in the Phase III study ...
Other Biology Technology:Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 2Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 3Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 4Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 5PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 2PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 3PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 4Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 2Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 3Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 4Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 5Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 6Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 7Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 8
cAMP Competitive immunoassay Assay Kit, HTRF from Cisbio
Goat Anti-DOCK 2 (E-15) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Goat Anti-PFK-2 car (P-17) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Anti-Ampicillin Monoclonal Antibody, Unconjugated, Clone 164-12-2 from Abcam
Biology Products: